- Datopotamab deruxtecan demonstrated statistically significant and clinically meaningful progression-free survival benefit in patients with HR-positive, HER2-low or negative breast cancer in TROPION-Breast01 Phase III trial AstraZeneca
- AstraZeneca, Daiichi hit first goal in breast cancer ADC trial FierceBiotech
- AstraZeneca, Daiichi breast cancer treatment succeeds in trial STAT
- Dr Liu on the 5-Year OS Data With Atezolizumab and Chemotherapy in ES-SCLC OncLive
- AstraZeneca and Daiichi’s breast cancer drug meets goal in study Reuters
- View Full Coverage on Google News
Tag Archives: Demonstrated
Tagrisso plus chemotherapy demonstrated strong improvement in progression-free survival for patients with EGFR-mutated advanced lung cancer in FLAURA2 Phase III trial – AstraZeneca
- Tagrisso plus chemotherapy demonstrated strong improvement in progression-free survival for patients with EGFR-mutated advanced lung cancer in FLAURA2 Phase III trial AstraZeneca
- AstraZeneca Tagrisso chemo combo cuts risk of lung cancer progression Seeking Alpha
- Immunotherapy Plus Chemo Improves Quality of Life in NSCLC Medscape
- AstraZeneca’s Tagrisso, chemo combination shows promise in lung cancer trial Reuters
- Docetaxel Plus Ramucirumab After Standard Frontline Treatment Elicits Responses in NSCLC OncLive
- View Full Coverage on Google News
Moderna and Merck Announce mRNA-4157 (V940), an Investigational Individualized Neoantigen Therapy, in Combination with KEYTRUDA(R) (Pembrolizumab), Demonstrated Superior Recurrence-Free Survival in Patients with High-Risk Stage III/IV Melano – Moderna Investor Relations
- Moderna and Merck Announce mRNA-4157 (V940), an Investigational Individualized Neoantigen Therapy, in Combination with KEYTRUDA(R) (Pembrolizumab), Demonstrated Superior Recurrence-Free Survival in Patients with High-Risk Stage III/IV Melano Moderna Investor Relations
- AACR 2023 – more hope for Moderna’s neoantigen immunotherapy Evaluate Pharma
- Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial The Lancet
- Phase 2 Data of Personalized Cancer Vaccine With Adjuvant Pembrolizumab for Resected High-Risk Melanoma Dermatology Times
- Merck clashes with AstraZeneca in biliary tract cancer FiercePharma
- View Full Coverage on Google News
Moderna and Merck Announce mRNA-4157 (V940), an Investigational Individualized Neoantigen Therapy, in Combination with KEYTRUDA(R) (Pembrolizumab), Demonstrated Superior Recurrence-Free Survival in Patients with High-Risk Stage III/IV Melano – news.modernatx.com
- Moderna and Merck Announce mRNA-4157 (V940), an Investigational Individualized Neoantigen Therapy, in Combination with KEYTRUDA(R) (Pembrolizumab), Demonstrated Superior Recurrence-Free Survival in Patients with High-Risk Stage III/IV Melano news.modernatx.com
- Including Anti-PD-1 in First-Line Ups Survival in Biliary Tract Cancer Medpage Today
- AACR 2023 – more hope for Moderna’s neoantigen immunotherapy evaluate.com
- Phase 2 Data of Personalized Cancer Vaccine With Adjuvant Pembrolizumab for Resected High-Risk Melanoma Dermatology Times
- Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial The Lancet
- View Full Coverage on Google News
Will Smith demonstrated his slapping technique on a little boy during King Richard Q&A in November
Disgraced Oscar winner Will Smith demonstrated his slapping technique on a little boy named Chris during a Q&A at a Variety-sponsored King Richard screening at the DGA Theater Complex in LA on November 11.
The masked little boy wanted to know precisely how the 53-year-old West Philly native ‘fakes being hit and beat up’ in the movies.
‘Alright, come here. C’mon. Come on up!’ Will (born Willard) said.
Disgraced Oscar winner Will Smith demonstrated his slapping technique on a little boy named Chris during a Q&A at a Variety-sponsored King Richard screening at the DGA Theater Complex in LA on November 11
‘I’m going to [clap my hands together] and you just turn your head when I go. And don’t fall down the steps.’
At that point, Smith’s concerned castmate Aunjuane Ellis stepped in to reposition Chris so he didn’t fall down the small staircase leading to the stage.
‘Mama instincts kicked in, thank you Aunjanue,’ the four-time Grammy winner smiled.
After practicing his stage combat a couple times with the child, Will said: ‘And then you just put it in a scene. So I need you to say, “Hey man, where’s my money?”‘
‘Alright, come here. C’mon. Come on up!’ The masked little boy wanted to know precisely how the 53-year-old West Philly native ‘fakes being hit and beat up’ in the movies
![Will said: 'I'm going to [clap my hands together] and you just turn your head when I go'](https://i.dailymail.co.uk/1s/2022/03/29/16/55958339-10664625-image-a-14_1648569337069.jpg)
Will said: ‘I’m going to [clap my hands together] and you just turn your head when I go’
After practicing his stage combat a couple times with the child, Smith said: ‘And then you just put it in a scene. So I need you to say, “Hey man, where’s my money?”‘
‘Where’s my money?’ The four-time Grammy winner then pretended to slap the boy and gave him a high five and a fist bump as the audience of 500 voters applauded
Chris (born Christopher) repeated: ‘Where’s my money?’
Smith then pretended to slap the boy and gave him a high five and a fist bump as the audience of 500 voters applauded.
The unearthed footage came the day after the Bel-Air executive producer issued a lawyer and publicist-approved apology for his violent assault against Chris Rock via Instagram with the comments turned off.
‘Violence in all of its forms is poisonous and destructive. My behavior at last night’s Academy Awards was unacceptable and inexcusable,’ Will – who boasts 251.4M social media followers – wrote in his statement.
‘My behavior was unacceptable and inexcusable’: The unearthed footage came the day after Will issued a lawyer and publicist-approved apology for his violent assault against Chris Rock via Instagram with the comments turned off
She suffers from alopecia: The 57-year-old comedian was presenting the trophy for best documentary when he joked about Smith’s 50-year-old wife (R) starring in a sequel to Ridley Scott’s 1997 movie G.I. Jane
Security did not escort him out of the building: The Bel-Air executive producer was laughing until he saw Jada’s uncomfortable reaction to the wisecrack and then stormed the stage and slapped Chris (L) across the face in retaliation
Kept his composure: Rock – who was reportedly unaware of Pinkett’s hair loss – has six months to decide whether to press formal charges for his very public assault, and ticket prices have surged for his 38-date Ego Death World Tour
‘Jokes at my expense are a part of the job, but a joke about [my wife] Jada’s medical condition was too much for me to bear and I reacted emotionally. I would like to publicly apologize to you, Chris. I was out of line and I was wrong. I am embarrassed and my actions were not indicative of the man I want to be.
‘There is no place for violence in a world of love and kindness. I would also like to apologize to the Academy, the producers of the show, all the attendees, and everyone watching around the world. I would like to apologize to the Williams Family and my King Richard Family. I deeply regret that my behavior has stained what has been an otherwise gorgeous journey for all of us. I am a work in progress.’
The 57-year-old comedian was presenting the trophy for best documentary when he joked about Smith’s 50-year-old wife – who suffers from alopecia – starring in a sequel to Ridley Scott’s 1997 movie G.I. Jane.
The Will co-author was laughing until he saw Jada’s uncomfortable reaction to the wisecrack and then stormed the stage and slapped Chris across the face in retaliation. Security did not escort him out of the building.
Getting jiggy with it! Will’s apology seemed much more like damage control considering his gaslit acceptance speech condoning violence, and how unbothered he was singing along to his own songs at the Vanity Fair Oscar Party in Beverly Hills
Smith joked, ‘You can’t invite people from Philly or Baltimore nowhere,’ and his 23-year-old son Jaden was so proud of his blatant assault in front of millions of viewers, he tweeted: ‘And that’s how we do it’
The Academy ‘condemned’ the Will co-author’s actions and ‘have officially started a formal review around the incident and will explore further action and consequences in accordance with our bylaws, standards of conduct and California law’
Rock – who was reportedly unaware of Pinkett’s hair loss – has six months to decide whether to press formal charges for his very public assault, and ticket prices have surged for his 38-date Ego Death World Tour.
Will’s apology seemed much more like damage control considering his gaslit acceptance speech condoning violence, and how unbothered he was singing along to his own songs at the Vanity Fair Oscar Party in Beverly Hills.
Smith joked, ‘You can’t invite people from Philly or Baltimore nowhere,’ and his 23-year-old son Jaden was so proud of his blatant assault in front of millions of viewers, he tweeted: ‘And that’s how we do it.’
The Academy ‘condemned’ the Welcome to Earth host’s actions and ‘have officially started a formal review around the incident and will explore further action and consequences in accordance with our bylaws, standards of conduct and California law.’
Canceled? And while Will could be ejected from the organization, the biggest loser might end up being Reinaldo Marcus Green’s critically-acclaimed biopic on Venus and Serena Williams’ tennis coach father Richard
Lost the plot: The film has only earned $38.1M of its $50M budget back at the global box office, and many HBO Max subscribers might avoid streaming it after the whole horrifying debacle
And while Will could be ejected from the organization, the biggest loser might end up being Reinaldo Marcus Green’s critically-acclaimed biopic on Venus and Serena Williams’ tennis coach father Richard.
The film has only earned $38.1M of its $50M budget back at the global box office, and many HBO Max subscribers might avoid streaming it after the whole horrifying debacle.
Smith has six upcoming projects – including hosting Lukas Kaiser’s comedian docuseries This Joka and starring as Peter in Antoine Fuqua’s action thriller Emancipation.
AI Is Discovering Patterns in Pure Mathematics That Have Never Been Seen Before
We can add suggesting and proving mathematical theorems to the long list of what artificial intelligence is capable of: Mathematicians and AI experts have teamed up to demonstrate how machine learning can open up new avenues to explore in the field.
While mathematicians have been using computers to discover patterns for decades, the increasing power of machine learning means that these networks can work through huge swathes of data and identify patterns that haven’t been spotted before.
In a newly published study, a research team used artificial intelligence systems developed by DeepMind, the same company that has been deploying AI to solve tricky biology problems and improve the accuracy of weather forecasts, to unknot some long-standing math problems.
“Problems in mathematics are widely regarded as some of the most intellectually challenging problems out there,” says mathematician Geordie Williamson from the University of Sydney in Australia.
“While mathematicians have used machine learning to assist in the analysis of complex data sets, this is the first time we have used computers to help us formulate conjectures or suggest possible lines of attack for unproven ideas in mathematics.”
The team shows AI advancing a proof for Kazhdan-Lusztig polynomials, a math problem involving the symmetry of higher-dimensional algebra that has remained unsolved for 40 years.
The research also demonstrated how a machine learning technique called a supervised learning model was able to spot a previously undiscovered relationship between two different types of mathematical knots, leading to an entirely new theorem.
Knot theory in math plays into various other challenging fields of science as well, including genetics, fluid dynamics, and even the behavior of the Sun’s corona. The discoveries that AI makes can therefore lead to advances in other areas of research.
“We have demonstrated that, when guided by mathematical intuition, machine learning provides a powerful framework that can uncover interesting and provable conjectures in areas where a large amount of data is available, or where the objects are too large to study with classical methods,” says mathematician András Juhász from the University of Oxford in the UK.
One of the benefits of machine learning systems is the way that they can look for patterns and scenarios that programmers didn’t specifically code them to look out for – they take their training data and apply the same principles to new situations.
The research shows that this sort of high-speed, ultra-reliable, large-scale data processing can act as an extra tool working with mathematicians’ natural intuition. When you’re dealing with complex, lengthy equations, that can make a significant difference.
The researchers hope that their work leads to many further partnerships between academics in the fields of mathematics and artificial intelligence, opening up the opportunity for findings that would otherwise be undiscovered.
“AI is an extraordinary tool,” says Williamson. “This work is one of the first times it has demonstrated its usefulness for pure mathematicians, like me.”
“Intuition can take us a long way, but AI can help us find connections the human mind might not always easily spot.”
The research has been published in Nature.
NeuroRx Announces ZYESAMI™ (aviptadil, RLF-100) Met the Primary Endpoint of Its Phase 2b/3 Clinical Trial and Also Demonstrated a Meaningful Benefit in Survival from Critical COVID-19
RADNOR, Pa., March 29, 2021 /PRNewswire/ — NeuroRx, Inc. today reports 60-day results of the Phase 2b/3 trial of intravenously-administered ZYESAMI™ (aviptadil acetate) for the treatment of respiratory failure in critically-ill patients with COVID-19, which is being developed in collaboration with Relief Therapeutics Holding AG (SIX:RLF,OTCQB:RLFTF). Across all patients and sites, ZYESAMI™ met the primary endpoint for successful recovery from respiratory failure at days 28 (P = .014) and 60 (P = .013) and also demonstrated a meaningful benefit in survival (P = < .001) after controlling for ventilation status and treatment site.
In addition to the robust overall significance across all 196 treated patients at all 10 clinical sites, the prespecified analysis of recovery from respiratory failure is clinically and statistically significant in the 127 patients treated by High Flow Nasal Cannula (HFNC) (P = .02), compared to those treated with mechanical or non-invasive ventilation at tertiary care hospitals. In this group, ZYESAMI™ patients had a 71% chance of successful recovery by day 28 vs. 48% in the placebo group (P = .017) and a 75% rate of successful recovery by day 60 vs. 55% in the placebo group (P = .036). Eighty-four percent (84%) of HFNC patients treated at tertiary medical centers with ZYESAMI™ survived to day 60 compared with 60% of those treated with placebo (P = .007).
To the company’s knowledge, ZYESAMI™ is the first COVID-19 therapeutic to demonstrate advantages in both survival and recovery from critical COVID-19 in a randomized, double-blind multicenter trial. On the basis of these findings, NeuroRx plans to apply immediately to the United States Food and Drug Administration (“FDA”) for Emergency Use Authorization (EUA) and to subsequently submit a New Drug Application (NDA).
Recovery from respiratory failure (without relapse) with discharge from acute care and survival through the observation period was the prespecified primary endpoint specified by FDA for the study, originally intended to be assessed at 28 days and then extended to 60 days based on recently-published FDA guidance. The above analysis includes all 196 participants who were randomized and treated in the placebo-controlled, double-blind clinical trial (www.clinicaltrials.gov NCT04311697) conducted at 10 US hospitals. Treatment with ZYESAMI™ or placebo was in addition to standard of care treatment that included steroids, convalescent plasma, antiviral therapy, anticoagulants, and various anti-cytokine drugs.
NeuroRx has announced the commencement of a clinical trial of inhaled ZYESAMI™ for the treatment of patients with moderate and severe COVID-19 with the aim of preventing progression to respiratory failure. NeuroRx has also announced the inclusion of inhaled ZYESAMI™ in the I-SPY clinical trial platform for patients with COVID-19 respiratory failure. The company has signed a clinical trial participation agreement with the National Institutes of Health.
The study’s coordinating committee, including Professors Dushyantha Jayaweera, MD, FACP (University of Miami), Richard Lee, MD, (UC Irvine), and J. Georges Youssef, MD (Houston Methodist Hospital) commented, “The 60-day observation framework implemented last month by FDA for critically ill patients with COVID-19 is more consistent with the clinical course of this lethal disease than the 28-day time frame originally adapted from other conditions that cause respiratory distress. The association of baseline oxygenation status (high flow nasal oxygen vs. ventilation) is not surprising in that patients who require mechanical or noninvasive ventilation in order to maintain blood oxygen are likely to have substantially more damage to the lining of their lungs compared to patients whose blood oxygen level can be maintained with high-flow oxygen delivered to the nose. The finding that patients fared substantially better in tertiary care centers as compared to regional hospitals may be influenced by the intensity of the public health crisis at the regional hospitals that participated in the study, all of which were operating at 200% or higher overcapacity in their intensive care units with implementation of temporary ICU beds and shortages of critical care staff.”
Prof. Jonathan Javitt, MD, MPH, Chairman and CEO of NeuroRx, said, “ZYESAMI has now demonstrated itself in a phase 2/3 trial, conducted under FDA Fast Track Designation, not only to shorten hospitalization (as was previously reported) but also to save lives and increase the likelihood of patients returning safely home to their families. In exactly 12 months, a lifesaving drug has advanced from concept to clinical success in partnership with Relief Therapeutics in the midst of a public health emergency that has claimed the lives of millions. Today’s findings confirm the often dramatic clinical success that has been seen in numerous patients treated in the US and abroad under emergency use protocols. We look forward to working with the National Institutes of Health, the Department of Defense, the FDA, and regulators around the world to bring this treatment to patients as quickly as possible.”
An investor conference call will be held today, March 29th at 8:30am EDT. Participants can dial (+1) 866-373-3402 or join via webcast at https://bit.ly/3sqPyDS. Those wishing to ask questions should submit those questions to [email protected].
NeuroRx, Inc. has signed an agreement to merge with Big Rock Acquisition Corp. Details may be viewed at http://irdirect.net/filings/viewer/index/1719406/000119312521019278/
About VIP in COVID-19
Vasoactive Intestinal Polypeptide (VIP) was first discovered by the late Dr. Sami Said in 1970. Although first identified in the lung, it was purified from the intestinal tract. VIP is now known to be produced throughout the body and to be primarily concentrated in the lungs. VIP has been shown in more than 100 peer-reviewed studies to have potent anti-inflammatory/anti-cytokine activity in animal models of respiratory distress, acute lung injury, and inflammation. Most importantly, VIP binds specifically to the alveolar type II cell (ATII) in the air sac (alveolus) of the lung. VIP stimulates ATII cells to make the surfactant that must coat the lining of the lung in order for the lung to exchange oxygen with the blood. Loss of surfactant causes respiratory failure and alveolar collapse, which is a hallmark of COVID-19.
COVID-19-related respiratory failure is caused by selective infection of the ATII cell by the SARS-CoV-2 virus. The ATII cells are vulnerable because of their (ACE2) surface receptors, which serve as the route of entry for the virus. Coronavirus infection of the ATII cell shuts down surfactant production, triggers the formation of inflammatory cytokines, and causes cell death (cytopathy). VIP is shown to upregulate surfactant production, block Coronavirus replication in the ATII cell, block cytokine synthesis, and prevent viral-induced cell death (cytopathy). To our knowledge, other than ZYESAMI™, no currently proposed treatments for COVID-19 specifically target this mechanism of action.
About NeuroRx, Inc.
NeuroRx draws upon more than 100 years of collective drug development experience from senior executives of AstraZeneca, Eli Lilly, Novartis, Pfizer, and PPD. In addition to its work on Aviptadil, NeuroRx has been awarded Breakthrough Therapy Designation and a Special Protocol Agreement to develop NRX-101 in suicidal bipolar depression and is currently in Phase 3 trials. Its executive team is led by Prof. Jonathan C. Javitt, MD, MPH, who has served as a health advisor to four Presidential administrations and worked on paradigm-changing drug development projects for Merck, Allergan, Pharmacia, Pfizer, Novartis, and Mannkind, together with Robert Besthof, MIM, who served as the Global Vice President (Commercial) for Pfizer’s Neuroscience and Pain Division. NeuroRx recently announced a plan to complete a business combination with Big Rock Partners Acquisition Corp (NASDAQ:BRPA) (“BRPA”), and intends to apply for listing on the NASDAQ under the proposed symbol “NRXP”.
About Relief Therapeutics Holding AG
Relief focuses primarily on clinical-stage programs based on molecules of natural origin (peptides and proteins) with a history of clinical testing and use in human patients or a strong scientific rationale. Currently, Relief is concentrating its efforts on developing new treatments for respiratory disease indications. Its lead drug candidate RLF-100™ (aviptadil) is being investigated in two placebo-controlled U.S. phase 2b/3 clinical trials in respiratory failure due to COVID-19. Relief also holds a patent issued in the United States and various other countries covering potential formulations of RLF-100™. Relief is listed on the SIX Swiss Exchange under the symbol RLF and quoted in the U.S. on OTCQB under the symbol RLFTF. www.relieftherapeutics.com.
Cautionary Note Regarding Forward Looking Statements
Statements contained in this press release that are not historical facts may be forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements generally relate to future events or NeuroRx’s future financial or operating performance. In some cases, you can identify forward-looking statements because they contain words such as “may,” “will,” “should,” “expects,” “plans,” “anticipates,” “could,” “intends,” “target,” “projects,” “contemplates,” “believes,” “estimates,” “predicts,” “potential” or “continue” or the negative of these words or other similar terms or expressions that concern NeuroRx’s expectations, strategy, plans or intentions. Such forward-looking statements may relate to, among other things, the outcome of any discussions or applications for the future use of ZYESAMI, the approvals, timing, and ability to complete the proposed business combination with BRPA, and the combined company’s ability to continue listing on Nasdaq after closing the proposed business combination. Such forward-looking statements do not constitute guarantees of future performance and are subject to a variety of risks and uncertainties. NeuroRx does not undertake any obligation to update forward-looking statements as a result of new information, future events or developments or otherwise.
Additional Information and Where to Find It
This press release relates to a proposed business combination and related transactions (the “Transactions”) between NeuroRx and BRPA. This press release does not constitute an offer to sell or exchange, or the solicitation of an offer to buy or exchange, any securities, nor shall there be any sale of securities in any jurisdiction in which such offer, sale or exchange would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. BRPA has filed a registration statement on Form S-4 (“Registration Statement”), which includes a preliminary proxy statement for the solicitation of the approval of BRPA’s stockholders, a preliminary prospectus for the offer and sale of BRPA’s securities in the Transactions and a preliminary consent solicitation statement of NeuroRx, and other relevant documents with the SEC. The proxy statement/prospectus/consent solicitation statement will be mailed to stockholders of NeuroRx and BRPA as of a record date to be established for voting on the proposed business combination. INVESTORS AND SECURITY HOLDERS OF NEURORX AND BRPA ARE URGED TO READ THE REGISTRATION STATEMENT, PROXY STATEMENT/PROSPECTUS/CONSENT SOLICITATION STATEMENT AND OTHER RELEVANT DOCUMENTS THAT WILL BE FILED WITH THE SEC CAREFULLY AND IN THEIR ENTIRETY WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED TRANSACTIONS. Investors and security holders will be able to obtain free copies of the registration statement, proxy statement, prospectus and other documents containing important information about NeuroRx and BRPA once such documents are filed with the SEC, through the website maintained by the SEC at http://www.sec.gov. In addition, copies of the documents filed with the SEC by BRPA can be obtained free of charge on BRPA’s website at www.bigrockpartners.com or by directing a written request to BRPA at 2645 N. Federal Highway, Suite 230 Delray Beach, FL 33483.
Participants in the Solicitation
NeuroRx, BRPA and their respective directors and executive officers, under SEC rules, may be deemed to be participants in the solicitation of proxies of BRPA’s stockholders in connection with the proposed Transactions. Investors and securityholders may obtain more detailed information regarding the names and interests in the proposed Transactions of NeuroRx’s and BRPA’s respective directors and officers in BRPA’s filings with the SEC, including the proxy statement/consent solicitation statement/prospectus statement. You may obtain a free copy of these documents as described in the preceding paragraph.
CORPORATE CONTACT
Jonathan C. Javitt, M.D., MPH
Chairman and Chief Executive Officer
[email protected]
INVESTOR RELATIONS
Ryan Sheffield
[email protected]
(484) 254-6134, ext. 723
MEDIA RELATIONS
Greg Parasmo
[email protected]
(484) 254-6134, ext. 724
SOURCE NeuroRx